Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating restated by stock analysts at Maxim Group in a report issued on Wednesday.

The analysts wrote, “Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.””

A number of other research analysts also recently issued reports on TEVA. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Mizuho reissued a “hold” rating and issued a $16.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Barclays PLC reduced their price objective on shares of Teva Pharmaceutical Industries Limited from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, BTIG Research restated a “buy” rating and issued a $24.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Four equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $30.83.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 14.56% during trading on Wednesday, hitting $16.08. The stock had a trading volume of 78,842,847 shares. The stock’s market cap is $16.34 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $45.95. The stock’s 50 day moving average price is $17.05 and its 200-day moving average price is $27.05.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the firm posted $1.25 earnings per share. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.31 earnings per share for the current fiscal year.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-earns-hold-rating-from-maxim-group/1608451.html.

Institutional investors have recently bought and sold shares of the stock. Capital Research Global Investors grew its holdings in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Franklin Resources Inc. raised its position in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after acquiring an additional 6,685,844 shares in the last quarter. FMR LLC raised its position in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after acquiring an additional 6,115,853 shares in the last quarter. Capital World Investors raised its position in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after acquiring an additional 3,268,200 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after acquiring an additional 2,782,257 shares during the period. Hedge funds and other institutional investors own 56.77% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.